Quote | Cardiff Oncology Inc. (NASDAQ:CRDF)
Last: | $4.07 |
---|---|
Change Percent: | -1.75% |
Open: | $4.06 |
Close: | $4.07 |
High: | $4.129 |
Low: | $3.98 |
Volume: | 514,993 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
News | Cardiff Oncology Inc. (NASDAQ:CRDF)
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a r...
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth – – Enhanced clinic...
Message Board Posts | Cardiff Oncology Inc. (NASDAQ:CRDF)
Subject | By | Source | When |
---|---|---|---|
znewcar1: $CRDF 22% v1,2M c1.91 f44,677M H1.92 ML1.2 YL1.54 BO1.7& pushed to hod | znewcar1 | investorshangout | 01/18/2023 11:12:04 PM |
znewcar1: CRDF 35% v8,8M c2.25 f43,3M H2.42 BO1.7 and pushed to HOD | znewcar1 | investorshangout | 06/09/2022 9:49:50 PM |
znewcar1: CRDF 25% v1,6M c1.70 f43,3M H1.73 MH1.13 BO1.4 and pushed | znewcar1 | investorshangout | 06/08/2022 3:14:09 AM |
Baird apparently think it is worthwhile to remain | oxnous | investorshub | 01/19/2022 8:52:05 PM |
So did people not think the data was | pipette | investorshub | 01/19/2022 2:13:47 AM |
News, Short Squeeze, Breakout and More Instantly...
Cardiff Oncology Inc. Company Name:
CRDF Stock Symbol:
NASDAQ Market:
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a r...
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth – – Enhanced clinic...
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhib...